BioLineRx Presents Positive Preclinical Results Of BL-8040 - Quick Facts

(RTTNews) - Biopharmaceutical development company BioLineRx (BLRX), Tuesday said that positive preclinical results of BL-8040 for the treatment of Acute Myeloid Leukemia or AML and other hematological indications, have been presented as a poster at the 55th Annual Meeting of the American Society of Hematology.

BL-8040 is a novel, potent and selective inhibitor of the CXCR4 chemokine receptor, which is normally activated by the chemokine ligand CXCL12. The data show that BL-8040 is efficient in inducing the death of AML cancer cells both in vitro and in a humanized mouse model. In addition, the ability of BL-8040 to induce mobilization of AML cells from the bone marrow into the blood circulation enhanced the chemotherapeutic effect of ARA-C, one of the standard-of-care chemotherapies for AML.

Kinneret Savitsky, Chief Executive Officer of BioLineRx, said: " These promising results further support the data we have accumulated to date, all indicating that BL-8040 has the potential to significantly improve personalized treatment for AML patients. We are looking forward to the partial results of the Phase 2 clinical trial in humans expected this month, with final results expected in the second half of 2014. Furthermore, based on the new pre-clinical data, we intend to perform a specific review of efficacy in the current Phase 2 study regarding those patients with the FLT3 mutation."